AR124841A1 - Compuestos antibacterianos - Google Patents
Compuestos antibacterianosInfo
- Publication number
- AR124841A1 AR124841A1 ARP220100257A ARP220100257A AR124841A1 AR 124841 A1 AR124841 A1 AR 124841A1 AR P220100257 A ARP220100257 A AR P220100257A AR P220100257 A ARP220100257 A AR P220100257A AR 124841 A1 AR124841 A1 AR 124841A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkylene
- membered heterocycloalkyl
- cycloalkyl
- unsubstituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000000844 anti-bacterial effect Effects 0.000 title 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- -1 -N(CH3)2 Chemical group 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
En el presente documento se proporcionan compuestos heterocíclicos y composiciones farmacéuticas que comprenden dichos compuestos que son útiles para inhibir el crecimiento de bacterias gramnegativas. Los compuestos y las composiciones en cuestión son útil es para el tratamiento de infecciones bacterianas, tales como neumonía. Reivindicación 1: Un compuesto de la fórmula (1) o una sal, solvato o profármaco farmacéuticamente aceptable de este, caracterizado porque: R¹ es alquilo C₁₋₄; R²ᵃ y R²ᵇ son independientemente hidrógeno, halógeno o alquilo C₁₋₄; R³ es hidrógeno, -(alquileno C₁₋₄)-OH o -(alquileno C₁₋₄)-NH₂; R⁴ es hidrógeno o alquilo C₁₋₄; cada R⁵ y R⁶ es independientemente hidrógeno, halógeno o alquilo C₁₋₄; R⁷ es alquilo C₁₋₆, alcoxi C₁₋₆, heteroalquilo C₁₋₆, cicloalquilo C₃₋₆, heterocicloalquilo de 4 a 6 miembros, -O-(cicloalquilo C₃₋₆), -O-(heterocicloalquilo de 4 a 6 miembros), -(alquileno C₁₋₄)-(cicloalquilo C₃₋₆), (alquileno C₁₋₄)-(heterocicloalquilo de 4 a 6 miembros), -O-(alquileno C₁₋₄)-(cicloalquilo C₃₋₆), -O-(alquileno C₁₋₄)-(heterocicloalquilo de 4 a 6 miembros), -(alquileno C₁₋₄)-O-(cicloalquilo C₃₋₆) o -(alquileno C₁₋₄)-O-(heterocicloalquilo de 4 a 6 miembros); donde el alquilo, alcoxi, heteroalquilo, cicloalquilo o heterocicloalquilo no está sustituido o está sustituido por 1, 2 ó 3 grupos seleccionados independientemente entre -OR⁸, -N(R⁸)₂, -CO₂R⁸, CON(R⁸)₂, -CH₂N(R⁸)₂, -NHCOR⁸, -NHSO₂R⁸, -CH₂CN, alquilo C₁₋₄, hidroxialquilo C₁₋₄, -C(=O)-hidroxialquilo C₁₋₄, metoxialquilo C₁₋₄ y aminoalquilo C₁₋₄; cada R⁸ es independientemente hidrógeno, alquilo C₁₋₄, -C(=O)-alquilo C₁₋₄ o heterocicloalquilo de 4 a 6 miembros, donde el alquilo o heterocicloalquilo no está sustituido o está sustituido por 1, 2, 3 ó 4 grupos seleccionados de manera independiente de -F, -CN, -OH, -CH₂OH, -NH₂, -OMe, -N(CH₃)₂, -CO₂H, -CONH₂, -SO₂CH₃, -C(=NH)NH₂, fenilo y heteroarilo monocíclico el cual no está sustituido o está sustituido por 1 ó 2 grupos seleccionados de -F, -CN, -OH, -NH₂, -OMe, N(CH₃)₂, -CO₂H, -CONH₂ y -SO₂CH₃; o dos R⁸ unido al mismo nitrógeno se unen para formar un heterocicloalquilo de 4 a 6 miembros no está sustituido o sustituido por 1, 2 ó 3 grupos seleccionados de manera independiente de -F, -CN, -OH, -NH₂, -OMe, -CO₂H, -CONH₂ y SO₂CH₃; s es 1 ó 2; y t es 1 ó 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163148261P | 2021-02-11 | 2021-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124841A1 true AR124841A1 (es) | 2023-05-10 |
Family
ID=82837229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100257A AR124841A1 (es) | 2021-02-11 | 2022-02-08 | Compuestos antibacterianos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240166609A1 (es) |
| EP (1) | EP4291550A1 (es) |
| JP (1) | JP2024507139A (es) |
| CN (1) | CN117279897A (es) |
| AR (1) | AR124841A1 (es) |
| TW (1) | TW202246218A (es) |
| WO (1) | WO2022173758A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019345150A1 (en) * | 2018-09-20 | 2021-05-13 | Blacksmith Medicines, Inc. | Antibacterial compounds |
| WO2024036176A1 (en) * | 2022-08-10 | 2024-02-15 | Blacksmith Medicines, Inc. | Antibacterial compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE540932T1 (de) * | 2006-08-31 | 2012-01-15 | Schering Corp | Hydantoin-derivate als antibakterielle wirkstoffe |
| WO2015085238A1 (en) * | 2013-12-05 | 2015-06-11 | The Regents Of The University Of California, A California Corporation | Inhibitors of lpxc |
| PT3233843T (pt) * | 2014-12-16 | 2019-11-26 | Novartis Ag | Compostos de ácido isoxazol hidroxámico como inibidores de lxpc |
| WO2018216822A1 (en) * | 2017-05-25 | 2018-11-29 | Taisho Pharmaceutical Co., Ltd. | Novel imidazole derivatives |
-
2022
- 2022-02-08 AR ARP220100257A patent/AR124841A1/es unknown
- 2022-02-08 US US18/264,838 patent/US20240166609A1/en active Pending
- 2022-02-08 CN CN202280027718.2A patent/CN117279897A/zh active Pending
- 2022-02-08 TW TW111104618A patent/TW202246218A/zh unknown
- 2022-02-08 WO PCT/US2022/015682 patent/WO2022173758A1/en active Application Filing
- 2022-02-08 JP JP2023548567A patent/JP2024507139A/ja active Pending
- 2022-02-08 EP EP22753215.7A patent/EP4291550A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202246218A (zh) | 2022-12-01 |
| CN117279897A (zh) | 2023-12-22 |
| WO2022173758A1 (en) | 2022-08-18 |
| EP4291550A1 (en) | 2023-12-20 |
| US20240166609A1 (en) | 2024-05-23 |
| JP2024507139A (ja) | 2024-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124841A1 (es) | Compuestos antibacterianos | |
| AR105643A1 (es) | COMPUESTOS ANTIVIRALES DE FOSFODIAMIDA DE ÉSTER DE b-AMINOÁCIDO | |
| AR106945A2 (es) | Compuestos de isoindolina y composiciones farmacéuticas de los mismos | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR096332A1 (es) | Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih | |
| AR086096A1 (es) | Derivados de nucleosidos 2’-ciano sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| AR042956A1 (es) | Inhibidores de girasa y usos de los mismos | |
| HRP20160623T1 (hr) | Inhibitori proteinske kinaze | |
| AR087757A1 (es) | Inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7, sus composiciones farmaceuticas y sus aplicaciones terapeuticas | |
| AR095192A1 (es) | Quinolina y quinazolinamidas como modulares de canales de sodio | |
| AR092959A1 (es) | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR108906A1 (es) | Heterociclos de biarilmetilo | |
| AR092307A1 (es) | Derivados de manosa para el tratamiento de infecciones bacterianas | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| CY1114081T1 (el) | Σπειροοξετανικα νουκλεοσιδια ουρακιλης ονες | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR107170A1 (es) | Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih | |
| AR119010A1 (es) | Compuestos, composiciones y métodos de uso | |
| AR109437A1 (es) | Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades | |
| AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR047008A1 (es) | Compuestos de 4-tetrazolil-4-fenilpiperidina como agonistas de los receptores opioides y agentes terapeuticos de utilidad para el tratamiento del dolor y composiciones farmaceuticas que los contienen como principio activo en combinacion con otros agentes terapéuticos. | |
| AR087792A1 (es) | Compuestos heterociclicos tetraciclicos y metodos para el uso de los mismos en el tratamiento de enfermedades virales | |
| AR106297A1 (es) | Compuestos macrocíclicos modificados como inhibidores selectivos de la quinasa cdk9 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |